IL17A and fungal infectious disease: Considering the essential role of IL-17/IL-17RA in antifungal immunity it is surprising that only mild cases of candidiasis have thus far been reported with Secukinumab treatment, yet patients on this or similar therapeutics should be monitored for fungal infections going forward [91].